CLARITY PHARMACEUTICALS LTD(CU6.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

CU6.AU CLARITY PHARMACEUTICALS LTD

Trading 11-01 14:31:15 AEDT

6.69

-0.14

-2.05%

High6.80	Low6.65	Vol353.89K
Open6.74	D1 Closing6.83	Amplitude2.27%
Mkt Cap2.14B	Tradable Cap1.50B	Total Shares320.21M
T/O2.38M	T/O Rate0.16%	Tradable Shares223.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":6.69,"timestamp":1730431875047,"preClose":6.83,"halted":0,"volume":353888,"delay":0,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":223967106,"shares":320211465,"eps":-0.154999,"marketStatus":"Trading","change":-0.14,"latestTime":"11-01 14:31:15 AEDT","open":6.74,"high":6.8,"low":6.645,"amount":2376938.38,"amplitude":0.022694,"askPrice":6.71,"askSize":2145,"bidPrice":6.69,"bidSize":3060,"shortable":3,"etf":0,"ttmEps":-0.154999,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1730437200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":6.83,"openAndCloseTimeList":[[1730415600000,1730437200000]],"volumeRatio":0.363634,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/CU6.AU/wiki","defaultTab":"wiki","newsList":[{"id":"2479761339","title":"Clarity Pharmaceuticals Ltd's (ASX:CU6) top owners are individual investors with 58% stake, while 18% is held by insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2479761339","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479761339?lang=en_us&edition=fundamental","pubTime":"2024-10-31 05:06","pubTimestamp":1730322413,"startTime":"0","endTime":"0","summary":"The considerable ownership by individual investors in Clarity Pharmaceuticals indicates that they collectively have a greater say in management and business strategy. A total of 25 investors have a majority stake in the company with 41% ownership. A look at the shareholders of Clarity Pharmaceuticals Ltd  can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 58% ownership. Put another way, the group faces the maximum upside potential .Meanwhile, individual insiders make up 18% of the company’s shareholders. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders.In the chart below, we zoom in on the different ownership groups of Clarity Pharmaceuticals.Check out our latest analysis for Clarity Pharmaceuticals. The definition of company insiders can be subjective and does vary between jurisdictio","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TLyt5D16lsSwRjJRVjlUTA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clarity-pharmaceuticals-ltds-asx-cu6-210653161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["CU6.AU","BK7096"],"gpt_icon":1},{"id":"2479240904","title":"Clarity Pharmaceuticals Insiders Got A Good Deal Selling At AU$1.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2479240904","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479240904?lang=en_us&edition=fundamental","pubTime":"2024-10-29 08:52","pubTimestamp":1730163173,"startTime":"0","endTime":"0","summary":"While it’s been a great week for Clarity Pharmaceuticals Ltd ( ASX:CU6 ) shareholders after stock gained 11%, company...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-insiders-got-a-good-deal-selling-at","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","BK4581","CU6.AU","IE00BKVL7J92.USD","LU1074936037.SGD","LU0971096721.USD","LU1162221912.USD","LU0314104364.USD","LU2357305700.SGD","LU1989772923.USD","LU0320765646.SGD","LU1989772840.SGD","BK4504","LU0106831901.USD","BK4534","IE00BZ1G4Q59.USD","BK4585","LU1668664300.SGD","LU0225283273.USD","LU0098860793.USD","BK4588","LU0267386448.USD","LU1548497426.USD","LU1363072403.SGD","LU1720051108.HKD","LU1720051017.SGD","BK4127"],"gpt_icon":0},{"id":"2476432429","title":"ASX Market Close: Index pulls back over China concerns | October 18, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2476432429","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476432429?lang=en_us&edition=fundamental","pubTime":"2024-10-18 14:01","pubTimestamp":1729231260,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.87% at 8283 points to finish the week.The bourse’s losses accumulated throughout the day, as investors remain nervous about the strength of the Chinese economy.All sectors finished in the red and Utilities was the worst performer, down 3.48%, followed by Real Estate, down 1.96% and Discretionary, down 1.89%.Talga Group  closed up 6.67% on news of approval of its exploitation concession for its natural graphite mine in northern Sweden.Clarity Pharmaceuticals  finished up 4.15% after broker Bell Potter reaffirmed its speculative buy rating and $10.00 price target.BSA  closed up 12.37% on its quarterly report. Revenue came in 35% higher year over year at $77 million and EBITDA jumped 48% to $6.5 million.Flight Centre  closed down20.44% after releasing a trading update which investors found lacking in clarity.APA  shares dropped 6.28% after its main shareholder Unisuper sold $500 million worth of shares late yesterday.Alcoa  closeddown 7.45% one day after dropping ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-pulls-back-over-china-concerns-october-18-2024-2024-10-18/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["APA.AU","BK4585","CU6.AU","FLT.AU","BK4588","AA","BK7070","BK7064","BK7095","AAI.AU","BK7096","BK7148","TLG.AU","BK7081","BSA.AU","BK4153"],"gpt_icon":0},{"id":"2476983604","title":"Why this speculative ASX stock could rise ~50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476983604","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476983604?lang=en_us&edition=fundamental","pubTime":"2024-10-18 08:07","pubTimestamp":1729210037,"startTime":"0","endTime":"0","summary":"If you have a high tolerance for risk, then it could be worth considering the speculative ASX stock in this article. That's the view of analysts at Bell Potter, which are tipping its shares to rise very strongly from where they trade today. Which speculative ASX stock?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/18/why-this-speculative-asx-stock-could-rise-50/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","CU6.AU"],"gpt_icon":1},{"id":"2476594588","title":"Copper-67 SAR-bisPSMA updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2476594588","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476594588?lang=en_us&edition=fundamental","pubTime":"2024-10-16 21:03","pubTimestamp":1729083780,"startTime":"0","endTime":"0","summary":"The third participant of cohort 4  of the SECuRE trial1 has now completed the Dose Limiting Toxicity  period after a second dose of 12GBq of 67Cu-SAR-bisPSMA, following on from the announcement dated 12 September 20242.The patient is a 93-year-old with a history of prostate cancer of over 26 years who previously failed multiple lines of therapy. No DLTs were reported after 2 doses of 12GBq of 67Cu-SAR-bisPSMA. The only adverse event  the patient experienced was moderate nausea after the first dose, which resolved.The safety profile of multiple doses of 67Cu-SAR-bisPSMA remains favourable. Almost all AEs related to 67Cu-SAR-bisPSMA in cohort 4 were mild to moderate, with the majority having either resolved or improved at the last assessment.Preliminary efficacy assessment from cohort 4 showed that all 3 participants had reductions in prostate-specific antigen  levels following 2 doses of 12GBq of 67Cu-SAR-bisPSMA, with the largest drop being 95.7% to date.Complete response with 2 doses ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zFWEWZjroafrlrXJeAwiQA--~B/aD00MDA7dz0zMjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/adbeffb8dbb4603fc7948e4791fd991a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zFWEWZjroafrlrXJeAwiQA--~B/aD00MDA7dz0zMjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/adbeffb8dbb4603fc7948e4791fd991a"],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/copper-67-sar-bispsma-updates-130300889.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/copper-67-sar-bispsma-updates-130300889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["SAR","BK4192","BK4217","PET","CU6.AU","BK7084","BK4588","PSA","BK4585","DLT.AU","SAR.AU","BK7096","BK4135","BK4138","PET.AU","AE","BK4533","BK4084","BK7047"],"gpt_icon":0},{"id":"2475230806","title":"Clarity Pharmaceuticals Reports Promising Results in Prostate Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2475230806","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475230806?lang=en_us&edition=fundamental","pubTime":"2024-10-16 09:41","pubTimestamp":1729042915,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said its SECuRE trial for the radiopharmaceutical 67Cu-SAR-bisPSM reported favorable safety profiles and reductions in prostate-specific antigen (PSA) levels.Prelimin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","BK4533","BK4588","CU6.AU","PSA","BK7096","AUD","BK4217","BK4585","BK4084"],"gpt_icon":0},{"id":"2475616550","title":"Clarity Pharmaceuticals Ltd-Copper-67 SAR-Bispsma Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2475616550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475616550?lang=en_us&edition=fundamental","pubTime":"2024-10-16 06:33","pubTimestamp":1729031622,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241015:nTUE3DPND9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2475361592","title":"BRIEF-Clarity Pharmaceuticals Ltd - Amplify Trial Patient Recruitment To Commence In Early 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2475361592","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475361592?lang=en_us&edition=fundamental","pubTime":"2024-10-14 21:07","pubTimestamp":1728911267,"startTime":"0","endTime":"0","summary":"Oct 14  - Clarity Pharmaceuticals Ltd   :   * POSITIVE GUIDANCE FROM THE U.S. FDA ON 64CU-SAR-BISPSMA PHASE III TRIAL IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER   * CLARITY PHARMACEUTICALS LTD - AMPLIFY TRIAL PATIENT RECRUITMENT TO COMMENCE IN EARLY 2025Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2475369799","title":"Positive Guidance From the U.S. FDA on 64Cu-SAR-Bispsma Phase Iii Trial in Patients With Recurrence of Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475369799","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475369799?lang=en_us&edition=fundamental","pubTime":"2024-10-14 21:02","pubTimestamp":1728910922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nTUABNCLH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2475369051","title":"Clarity Pharmaceuticals Ltd - Amplify Trial Patient Recruitment to Commence in Early 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2475369051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475369051?lang=en_us&edition=fundamental","pubTime":"2024-10-14 21:02","pubTimestamp":1728910922,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241014:nTUABNCLH6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2475935729","title":"ASX Market Close: Index ascends as Gold and Iron Ore rise | October 14, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2475935729","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475935729?lang=en_us&edition=fundamental","pubTime":"2024-10-14 14:45","pubTimestamp":1728888300,"startTime":"0","endTime":"0","summary":"The ASX200 has closed up 0.47% at 8,252 points. Once again, the bourse closed within an inch of an all-time record, as buoyant sentiment shows no signs of abating.Gold stocks were amongst the best performers, as the Gold price maintains last weeks highs and has been US$2658 US dollars per ounce.Iron Ore climbed 2% higher, on news over the weekend of further Chinese stimulus and this drove the miners higher.To the sectors, the Materials sector was the best performer, up 1.3%, followed by HealthCare, up 0.9% and Financials, up 0.8%.The Energy sector was sold off heavily, down 1.25%, followed by IT, down 0.6% and Discretionary, down 0.47%.True North Copper  finished up 10.71%on news its mining and processing activities at the Cloncurry Copper Project  in Queensland are ramping up. The company is pushing towards production in Q1, 2025.Clarity Pharmaceuticals  closed down 1% on news of a new CEO and positive guidance from the FDA on its clinical trial in patients with recurring prostate can","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-index-ascends-as-gold-and-iron-ore-rise-october-14-2024-2024-10-14/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7093","TNC.AU","BK7070","NIS.AU","BK7096","WEB.AU","CU6.AU","JBY.AU","BK7145","LIC.AU","BK7095","CCP.AU"],"gpt_icon":0},{"id":"2475807699","title":"Clarity Pharmaceuticals to Start Phase Three Prostate Cancer Diagnostic Trial Following Positive Feedback from US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2475807699","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475807699?lang=en_us&edition=fundamental","pubTime":"2024-10-14 11:08","pubTimestamp":1728875330,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) will start a phase three trial of its 64Cu-SAR-bisPSMA diagnostic in patients with recurrent prostate cancer following a successful end-of-phase meeting with the US F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2475134809","title":"Clarity Pharmaceuticals Appoints CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2475134809","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475134809?lang=en_us&edition=fundamental","pubTime":"2024-10-14 10:07","pubTimestamp":1728871662,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  named Michelle Parker as chief executive, effective Oct. 11, succeeding Colin Biggin, according to a Monday filing with the Australian Securities Exchange.Biggin will serve as chief operating officer while remaining an executive director on the board, the filing said.Price : $6.94, Change: $-0.03, Percent Change: -0.43%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","CU6.AU","XKO.AU","BK4125","XAO.AU","XJO.AU","BK7096"],"gpt_icon":0},{"id":"2475808947","title":"BRIEF-Clarity Pharmaceuticals Announces Appointment Of Michelle Parker As Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475808947","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475808947?lang=en_us&edition=fundamental","pubTime":"2024-10-14 09:20","pubTimestamp":1728868826,"startTime":"0","endTime":"0","summary":"Oct 14 (Reuters) - Clarity Pharmaceuticals Ltd   :   * APPOINTMENT OF MICHELLE PARKER AS CHIEF EXECUTIVE OFFICERSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2475808668","title":"BRIEF-Clarity Pharmaceuticals Says FDA Gave Positive Feedback On Phase III Trial For Cu-Sar-Bispsma","url":"https://stock-news.laohu8.com/highlight/detail?id=2475808668","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475808668?lang=en_us&edition=fundamental","pubTime":"2024-10-14 09:16","pubTimestamp":1728868595,"startTime":"0","endTime":"0","summary":"Oct 14 (Reuters) - Clarity Pharmaceuticals Ltd   :   * U.S. FDA PROVIDED POSITIVE FEEDBACK ON PHASE III TRIAL FOR CU-SAR-BISPSMA DIAGNOSTIC IN PROSTATE CANCER PATIENTS WITH BCR Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2475876178","title":"Clarity Pharmaceuticals- U.S. FDA Provided Positive Feedback on Phase Iii Trial for Cu-SAR-Bispsma Diagnostic in Prostate Cancer Patients With Bcr","url":"https://stock-news.laohu8.com/highlight/detail?id=2475876178","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475876178?lang=en_us&edition=fundamental","pubTime":"2024-10-14 06:51","pubTimestamp":1728859876,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241013:nFWN3LN11F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2475876624","title":"Clarity Pharmaceuticals -  Appointment of Michelle Parker as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2475876624","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475876624?lang=en_us&edition=fundamental","pubTime":"2024-10-14 06:45","pubTimestamp":1728859550,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241013:nFWN3LN0WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"gpt_icon":0},{"id":"2473452541","title":"BRIEF-Clarity Pharmaceuticals Enters Clinical Manufacturing Agreement With Spectronrx","url":"https://stock-news.laohu8.com/highlight/detail?id=2473452541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473452541?lang=en_us&edition=fundamental","pubTime":"2024-10-08 09:15","pubTimestamp":1728350106,"startTime":"0","endTime":"0","summary":"Oct 8 (Reuters) - Clarity Pharmaceuticals Ltd   :   * ENTERS CLINICAL MANUFACTURING AGREEMENT FOR CU-64 SAR-BISPSMA WITH SPECTRONRXFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2473201430","title":"Clarity Pharmaceuticals - Enters Clinical Manufacturing Agreement for Cu-64 SAR-Bispsma With Spectronrx","url":"https://stock-news.laohu8.com/highlight/detail?id=2473201430","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473201430?lang=en_us&edition=fundamental","pubTime":"2024-10-08 06:52","pubTimestamp":1728341568,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nFWN3LJ0X9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"gpt_icon":0},{"id":"2469104020","title":"We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2469104020","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2469104020?lang=en_us&edition=fundamental","pubTime":"2024-09-24 05:49","pubTimestamp":1727128199,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. Indeed, Clarity Pharmaceuticals...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/we-think-clarity-pharmaceuticals-asxcu6-can-easily-afford-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CU6.AU","BK7096"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0194},{"period":"1month","weight":-0.2167},{"period":"3month","weight":0.0998},{"period":"6month","weight":0.8712},{"period":"1year","weight":5.599},{"period":"ytd","weight":2.5947}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":0.0074},{"period":"3month","weight":0.0091},{"period":"6month","weight":0.0502},{"period":"1year","weight":0.1788},{"period":"ytd","weight":0.1439}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.032433},{"month":2,"riseRate":0,"avgChangeRate":-0.090293},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.037643},{"month":4,"riseRate":0.666667,"avgChangeRate":0.263536},{"month":5,"riseRate":0.666667,"avgChangeRate":0.009599},{"month":6,"riseRate":1,"avgChangeRate":0.219023},{"month":7,"riseRate":1,"avgChangeRate":0.167286},{"month":8,"riseRate":0.5,"avgChangeRate":0.019329},{"month":9,"riseRate":0.25,"avgChangeRate":-0.092463},{"month":10,"riseRate":0.666667,"avgChangeRate":0.200658},{"month":11,"riseRate":0.333333,"avgChangeRate":0.05005},{"month":12,"riseRate":0.666667,"avgChangeRate":0.039681}],"exchange":"ASX","name":"CLARITY PHARMACEUTICALS LTD","nameEN":"CLARITY PHARMACEUTICALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CLARITY PHARMACEUTICALS LTD(CU6.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CLARITY PHARMACEUTICALS LTD(CU6.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CLARITY PHARMACEUTICALS LTD,CU6.AU,CLARITY PHARMACEUTICALS LTD股票,CLARITY PHARMACEUTICALS LTD股票老虎,CLARITY PHARMACEUTICALS LTD股票老虎国际,CLARITY PHARMACEUTICALS LTD行情,CLARITY PHARMACEUTICALS LTD股票行情,CLARITY PHARMACEUTICALS LTD股价,CLARITY PHARMACEUTICALS LTD股市,CLARITY PHARMACEUTICALS LTD股票价格,CLARITY PHARMACEUTICALS LTD股票交易,CLARITY PHARMACEUTICALS LTD股票购买,CLARITY PHARMACEUTICALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CLARITY PHARMACEUTICALS LTD(CU6.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CLARITY PHARMACEUTICALS LTD(CU6.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction